This is good news potentially. TL1A have the potential of helping with inflammatory bowel disease, and arthritis and inflammatory diseases but it won’t come out, until half a decade from now.
Biotech stock investors are hoping for a repeat performance from the suite of TL1A drugs.
Proving The Drug’s Merit
First, the companies are looking to prove the drugs’ merit in ulcerative colitis and Crohn’s disease. So far, that venture has paid off handsomely for the biotech stocks involved.
The repair of damage to genetic material (DNA) in the human body is carried out by highly efficient mechanisms that have not yet been fully researched. A scientific team led by Christian Seiser from MedUni Vienna’s Center for Anatomy and Cell Biology has now discovered a previously unrecognized control point for these processes.
This discovery could lead to a new approach for the development of cancer therapies aimed at inhibiting the repair of damaged cancer cells. The research work was recently published in the journal Nucleic Acids Research.
GSE1-CoREST is the name of the newly discovered complex that contains three enzymes that control DNA repair processes and could form the basis for novel cancer therapeutics. “In research, these proteins are already associated with cancer, but not in the context that we have now found,” emphasizes Seiser, who led the study in close collaboration with researchers from the Max Perutz Labs Vienna.
A recent study published in Nature Electronics discusses stretchable graphene–hydrogel interfaces for wearable and implantable bioelectronics.
Stretchable and conductive nanocomposites with mechanically soft, thin and biocompatible features play vital roles in developing wearable skin-like devices, smart soft robots and implantable bioelectronics.
Although several design strategies involving surface engineering have been reported to overcome the mechanical mismatch between the brittle electrodes and stretchable polymers, it is still challenging to realize monolithic integration of various components with diverse functionalities using the current ultrathin stretchable conductive nanocomposites. This is attributed to the lack of suitable conductive nanomaterial systems compatible with facile patterning strategies.
With depression affecting around 1 in 10 of us at some point during our lives, the need for new and improved treatments is a top priority for researchers – and it appears that spinal cord stimulation could be one route for experts to investigate.
A team led by researchers at the University of Cincinnati College of Medicine devised a pilot clinical trial in which a little black box was placed on the spinal cord of 20 volunteers with depression, with one electrode on the back and one on the right shoulder.
The box then delivered a specially customized, low-level electric buzz to half of the volunteers, for three sessions per week over eight weeks. This was shown to have a greater effect on depressive symptoms than the different, ‘placebo’ charge administered to the other half of the volunteers.
After Artemis 2 launches and before the crew sets course for the Moon, the crew will spend a day or so carrying out systems checks in Earth orbit. During this stage, the crew will also test their ability to rendezvous with the SLS’s Interim Cryogenic Propulsion Stage, which will serve as valuable practice for future docking maneuvers needed in later Artemis missions. The spacecraft’s orbit around Earth will be highly elliptical, ranging in altitude from about 115 miles (185 kilometers) to 46,000 miles (74,000 km) above Earth’s surface.
Once they receive approval to set course for the Moon, the four members of the Artemis 2 crew will embark on humanity’s first trip to the Moon’s neighborhood since 1972.
Artemis 2 will not land on or orbit the Moon, but will instead use several lunar-destination burns and course corrections to achieve a so-called free-return trajectory. This approach will bring the craft to within about 6,400 miles (10,000 km) of the Moon’s farside — and allow it to return to Earth even if the craft experiences an engine failure. The free-return trajectory will form a figure-eight around Earth and the Moon, and the Artemis 2 mission is expected to last about 10 days.
Hospitals in four states, as well as Washington D.C., have brought in some form of mask-wearing requirements amid an uptick in cases.
Now, astronomers led by Northwestern University have pinpointed the extraordinary object’s birthplace — and it’s rather curious, indeed.
Using images from NASA ’s Hubble Space Telescope, the researchers traced the FRB back to not one galaxy but a group of at least seven galaxies. The galaxies in the collection appear to be interacting with one another — perhaps even on the path to a potential merger. Such groups of galaxies are rare and possibly led to conditions that triggered the FRB.
The unexpected finding might challenge scientific models of how FRBs are produced and what produces them.
What actually happens is much weirder, and may help us understand more about quantum mechanics.
The quantum Cheshire cat effect draws its name from the fictional Cheshire Cat in the Alice in Wonderland story. That cat was able to disappear, leaving only its grin behind. Similarly, in a 2013 paper, researchers claimed quantum particles are able to separate from their properties, with the properties traveling along paths the particle cannot. They named this the quantum Cheshire cat effect. Researchers since have claimed to extend this further, swapping disembodied properties between particles, disembodying multiple properties simultaneously, and even “separating the wave-particle duality” of a particle.
Contextuality in Quantum Mechanics.
Discovery could be useful in developing new therapies for multiple sclerosis, neurodegenerative conditions, and brain cancer.
New research from Oregon Health & Science University for the first time reveals the function of a little-understood junction between cells in the brain that could have important treatment implications for conditions ranging from multiple sclerosis to Alzheimer’s disease, to a type of brain cancer known as glioma.
The study will be published today (January 12) in the journal Nature Neuroscience.
